RecruitingNCT06953622

Establishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale


Sponsor

Peking University Third Hospital

Enrollment

330 participants

Start Date

Jan 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

To establish a headache center in China that combines clinical, imaging and laboratory examinations, explore the feasible treatment options for migraine combined with patent foramen ovale, and search for the possible influencing factors, construct models that influence prognosis.


Eligibility

Inclusion Criteria3

  • Meet the diagnostic criteria for migraine in the International Classification of Headache (ICHD-3);
  • Confirmation of patent foramen ovale through transthoracic echocardiography(TTE) or transesophageal echocardiography(TEE)/right heart contrast echocardiography
  • Agree to participate in the study and sign the informed consent form.

Exclusion Criteria1

  • Can not sign the informed consent form or cooperate with follow-up.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGConservative treatment

Receive no antipaletet drug treatment and surgery

DRUGAntipaletet drug

Use of antipaletet drugs.

PROCEDUREPatent Foramen Ovale Closure

Receive the surgery of Patent Foramen Ovale


Locations(1)

Peking University Third Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06953622


Related Trials